Dr Douglas Argyll Robertson5 (1837-1909) was a Scottish Ophthalmologist and surgeon. Dr Robertson was the first to publish a description including post-op results following the use of a trephine in the surgical treatment of glaucoma in late 19th century. This would create a small hole in the sclera (anterior sclerotomy) that would drain aqueous Humor to lower IOP.
At the turn of the 20th Century, Dr Robert Henry Elliot6 (1865 – 1936) whom was a British ophthalmic surgeon and also an expert on snake venom published his work on Sclero-corneal trephining in the operative treatment of glaucoma
Read More
At the forefront of Interventional Glaucoma treatment, MIMS® creates a direct pathway from the anterior chamber to the sub-conjunctival space during the surgery, without implanting a stent.
It works by inserting a specially designed cutting tool into the sclera & removing a small channel of tissue. This channel will remain open & continuously drained, designed to effectively lower the IOP.
MIMS® is a lightweight surgical system intended for use by trained professional ophthalmologists. It’s intuitive to operate and requires fewer staff to assist in non-surgical environments. A central control touchscreen demonstrates the surgical parameters & a foot pedal initiates the precise handheld cutting tool movement.
Novel Glaucoma treatment practiced globally. Learn more about MIMS® surgical device innovation.
Medication reduction from baseline after 1 year1
IOP reduction from baseline after 1 and 3 years1-4
Medication reduction from baseline after 3 years2-4
MIMS® is a promising minimally invasive filtering surgical procedure. It is an implant-free filtering surgery ab interno. MIMS® requires the application of MMC. As with any filtering procedure, MIMS® requires preoperative and postoperative management.
MIMS® is a promising technology and technique that is minimally invasive, involves no implant, requires the use of MMC, and forms a bleb. The initial results are encouraging, and the FDA investigational process is underway. The procedure is currently being used and marketed in Europe and Israel. Real-world experience and published data will illuminate the path forward for MIMS®.
Additionally, as with all procedures, as more surgeons from around the world adopt MIMS®, the technique itself, pre- and postop- erative management, and methods of MMC application will continue to evolve and improve.
Minimally invasive anti-glaucoma surgical procedure performed with the new MIMS® surgical device was found satisfactory in open angle glaucoma patients after 3 years. The efficacy and safety (0% serious adverse events) results were found similar to other filtration procedures. However, the MIMS® procedure is simpler and faster than most other filtering procedures.
Having operated on a dozen patients with the MIMS® device and procedure, I can state that the device requires a very short learning curve, it is safe and it provides an alternative to the stent procedures. MIMS® can be easily used together with cataract surgery and it fits most glaucoma patients. The clinical data from Europe demonstrates efficacy similar to Trabeculectomy with less side effects. 97% of the patients do not require anti Glaucoma medication. The fact that nothing is left behind keeps future therapeutic options open which is a major advantage.
MIMS® is a stent-less procedure. It is safer and less invasive than traditional incisional surgery. It is quick and simple to master and it can be easily combined with cataract surgery
1. Voskanyan L., Ahmed I.I.K., Gershoni A. et al., «Minimally invasive micro sclerostomy (MIMS) procedure in the treatment of open-angle glaucoma». BMC Ophthalmol 24, 122 (2024).
2. Voskanyan L. et al., « Long Term Results Of Minimally Invasive Micro Sclerostomy (MIMS®)»,10th World Glaucoma Congress, June 30, 2023, Rome Italy.
3. Voskanyan L., «Long-term results of Minimally Invasive Micro Sclerostomy (MIMS®)», Poster presented at the 41st Congress of the ESCRS, September 9, 2023, Vienna, Austria.
4. Geffen N., «Ab interno sclerostomy», Glaucoma Surgery: New Techniques on the Horizon,presented at the 10th Congress of the WGC Congress, June 30, 2023 Rome, Italy
5. Robertson D.A., «Trephining the sclerotic: a new operation for glaucoma.», Royal London Ophthalmic Hospital Reports, (Volume 8), 1876.
6. Elliot, R.H., «Sclero-corneal trephining in the operative treatment of glaucoma», 186 Pages, 2nd ed. London: George Pulman & Sons,1914.
7. Junemann A.G.M. and Redfak R., «MIMS – minimally invasive micro-sclerostomy: A new filtering surgical procedure.» Concept Ophtalmology, August 2022.
8. Grover D.S, MD, MPH, «MINIMALLY INVASIVE MICRO SCLEROSTOMY – Reviewing the surgical steps and outcomes for a new filtration procedure.», GLAUCOMA TODAY, 2022.
9. Larkin H., «Stent-less Glaucoma Surgery, Expanded indications sought for minimally invasive technology.», EUROTIME, 2023.
10. «MIMS®: WHERE NOTHING GETS LEFT BEHIND, Introducing a stentless, simple, and rapid glaucoma treatment that effectively lowers IOP without invasive surgery», The Ophtalmologist, 2022.
11. Voskanyan L., “New arrival – a fresh approach to treating glaucoma.” Presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.
12. Paper presented at the 40th Congress of the ESCRS 2022 Congress, Bausch+Lomb Symposium, September 18, 2022; Milan, Italy.